Pharsight

Eliquis generic

Eliquis is a drug owned by Bristol Myers Squibb. It contains apixaban as the active ingredient. Eliquis was first authorized for market use on 28th December, 2012. The drug is available in the form of an oral tablet.

When will Eliquis generic be available?

Eliquis generic drug may be likely available after 24th February, 2031. The drug holds 2 patents, with patent 'US9326945 - Apixaban formulations' due to expire on this date. The other patent 'US6967208 - Lactam-containing compounds and derivatives thereof as factor Xa inhibitors' is set to expire earlier on 21st November, 2026.

Eliquis uses

Eliquis is primarily used for the prophylaxis of deep vein thrombosis and pulmonary embolism. It is also effective in reducing the risk of stroke and systemic embolism. The drug can be used for the treatment of pulmonary embolism (PE), reducing the risk of recurrent deep vein thrombosis (DVT), and treatment of deep vein thrombosis (DVT). It is also prescribed for reducing the risk of recurrent pulmonary embolism and prophylaxis of deep vein thrombosis (DVT). apixaban, the active ingredient in Eliquis, contributes to its effectiveness in these applications.

Eliquis patent expiration

Eliquis holds 2 patents, with the last one expiring on 24th February, 2031. The generics of Eliquis would likely become available post this date. Below are the details of the patent:

EPO Oppostions filed on Eliquis

Litigations filed on Eliquis

Eliquis dosage

Want to ask something?